How the BHF PROTECT-TAVI trial, with results expected soon, will impact that trend remains to be seen.
US hospitals pulled back on their use of cerebral embolic protection during TAVI after publication of the PROTECTED TAVR results, a new analysis affirms.
The proportion of procedures done with the Sentinel cerebral protection system (Boston Scientific) fell from 13.5% in the year prior to publication to 10.2% over the next year (P < 0.001) after the trial failed to demonstrate a significant reduction in periprocedural stroke with the device.
The trend was driven mostly by drops at centers that had been using the Sentinel device in more than 50% of their TAVI cases, Marwan Saad, MD, PhD (Rhode Island Hospital, Providence), and colleagues report in a research letter published online this week in JACC:…